NCT00244881View on ClinicalTrials.gov

A Phase II Study of AZD2171 in Breast Cancer Stage IV (10006202)

PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

August 31, 2007

Study Completion Date

December 31, 2007

Conditions
Male Breast CancerRecurrent Breast CancerStage IV Breast Cancer
Interventions
DRUG

cediranib maleate

Given orally

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

02115

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00244881 - A Phase II Study of AZD2171 in Breast Cancer Stage IV (10006202) | Biotech Hunter | Biotech Hunter